- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00005097
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
RATIONALE: Green tea extract contains ingredients that may inhibit the growth of actinic keratosis.
PURPOSE: Randomized phase II trial to determine the effectiveness of green tea extract in treating patients who have actinic keratosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES: I. Determine the efficacy of the green tea extract epigallocatechin gallate (Polyphenon E topical ointment) in causing complete clinical and histopathologic regression in patients with actinic keratoses. II. Determine duration of treatment with Polyphenon E necessary to cause regression in these patients. III. Describe pathophysiologic and molecular alterations in actinic keratoses and sun damaged skin that are not present in skin that is not sun damaged in these patients. IV. Determine the effects of this treatment on biomarkers for skin cancer in these patients.
OUTLINE: This is a randomized, double blind, placebo controlled study. One of the patient's arms is randomized to receive topical epigallocatechin gallate (Polyphenon E), the other arm to receive a placebo. Patients receive topical applications daily for 12 weeks, or until resolution of all actinic keratoses within the treatment field.
PROJECTED ACCRUAL: A minimum of 60 patients will be accrued for this study over 10 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Chao Family Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- participants multiple sites of actinic keratosis identified by clinical examination and the histologic confirmation of one lesion (Grade 1-3 as defined previously in "Clinical Grading") are eligible.
- No history of invasive cancer within 5 years (though non-melanoma skin cancer, stage I cervical cancer, or chronic lymphocytic leukemia (CLL) stage 0 will not be reason to exclude a patient); no severe metabolic disorders or other life-threatening acute or chronic disease; no additional x-ray or chemotherapy anticipated.
- Not requiring use of topical medications in areas being studied.
- Subjects must meet the Southwest Oncology Group performance status criteria of 0 - 1 (0= fully active, able to carry on all pre-disease activities without restriction [Karnofsky scale 90 - 100]; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, i.e. light housework or office work [Karnofsky scale 70 - 80]).
- Signed informed consent approved by the local Human Subjects Committee (Institutional Review Board).
Exclusion Criteria:
Use of the following systemic or local therapies for the periods specified, prior to entry into the study:
Within 2 weeks: topical medications, e.g. corticosteroids, alpha-hydroxyacids (glycolic acid, lactic acid) or retinoids (Retin-A) to the target lesions Within 4 weeks: systemic steroid therapy. Within 2 months: cryotherapy to the target lesions, laser resurfacing, chemical peels, topical application of 5-fluorouracil (5-FU) or masoprocol (Actinex) for treatment of actinic keratoses. Systemic treatment with chemotherapeutic agents, psoralens, immunotherapy, retinoids (Tegison, Accutane).
- Any medical condition which , in the opinion of the investigator, could preclude study participation
- Active infectious diseases such as tuberculosis (TB) or HIV that may affect the patient systemically and may also affect the immune system. Localized, minor infections such as sinusitis, uncomplicated urinary tract infection, otitis media, etc. will not be criteria for exclusion from the study.
- Use of any investigational drug in the previous 30 days.
- Any history of keloid formation.
- Pregnant or nursing patients.
- Participants who may be unreliable for the study, including those engaging in excessive alcohol intake or drug abuse, or participants who are unable to return for scheduled follow-up visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Polyphenon E & Placebo
Each subject will receive both the Polyphenon E and placebo, one on each arm. One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks. |
Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms.
One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner.
The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo.
Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical and histopathologic regression of actinic keratoses
Time Frame: 12 weeks
|
Measure efficacy of Polyphenon E in causing complete and clinical and histopathologic regression of actinic keratoses in comparison to placebo
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Frank L. Meyskens, MD, FACP, Chao Family Comprehensive Cancer Center
Publications and helpful links
General Publications
- Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL Jr. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002.
- Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, Meyskens FL. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 2003;163:165-71; discussion 264-6. doi: 10.1007/978-3-642-55647-0_15.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCI 98-31 / CDR0000067798
- UCIRVINE-N01-CN-85182 (Other Identifier: UC Irvine)
- NCI-P00-0142 (Registry Identifier: National Cancer Insitute)
- UCI 98-31 (Other Identifier: University of California, Irvine)
- 1998-420 (Other Identifier: University of California, Irvine)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-melanomatous Skin Cancer
-
Roswell Park Cancer InstituteCompletedNon-melanomatous Skin CancerUnited States
-
National Cancer Institute (NCI)CompletedPrecancerous Condition | Non-melanomatous Skin CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNon-melanomatous Skin Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedNon-melanomatous Skin CancerUnited States
-
Queen's Medical CenterCompletedNon-melanomatous Skin CancerUnited Kingdom
-
National Naval Medical CenterCompletedNon-melanomatous Skin CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedNon-melanomatous Skin Cancer
-
The Cleveland ClinicNational Cancer Institute (NCI)TerminatedNon-melanomatous Skin Cancer
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedNon-melanomatous Skin CancerUnited States
-
Baylor College of MedicineNational Cancer Institute (NCI)UnknownNon-Melanomatous Skin CancerUnited States
Clinical Trials on Polyphenon E and Placebo
-
Louisiana State University Health Sciences Center...Polyphenon PharmaCompleted
-
MediGeneCompletedCondylomata AcuminataUnited States, Argentina, Chile, Colombia, Mexico, Peru, Romania
-
University of LouisvilleNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedMild to Moderately Active Ulcerative ColitisUnited States
-
Louisiana State University Health Sciences Center...Columbia UniversityCompletedBreast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa DystrophicaFrance
-
Sherry ChowNational Cancer Institute (NCI)CompletedLung Cancer PreventionUnited States
-
University of ChicagoTerminatedDuctal Carcinoma in SituUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingProstate CarcinomaUnited States, Puerto Rico, Guam
-
Louisiana State University Health Sciences Center...National Center for Complementary and Integrative Health (NCCIH)Completed